News | May 13, 2025
Morepen Board proposed dividend after 23 years
Scores highest PAT of Rs. 118 crore in FY25
Scores highest PAT of Rs. 118 crore in FY25
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
This approval authorizes the company to export Ibuprofen to the Chinese markets
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Ami Organics’ Ankleshwar Unit II gets GMP compliant by PMDA Japan
Subscribe To Our Newsletter & Stay Updated
